Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Non-Current Deffered Revenue (2016 - 2018)

Viking Therapeutics (VKTX) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $12000.0 as the latest value for Q4 2018.

  • For Q4 2018, Non-Current Deffered Revenue changed N/A year-over-year to $12000.0; the TTM value through Dec 2018 reached $12000.0, changed N/A, while the annual FY2018 figure was $12000.0, N/A changed from the prior year.
  • Non-Current Deffered Revenue hit $12000.0 in Q4 2018 for Viking Therapeutics, up from $6054.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $31239.0 in Q4 2015 and bottomed at $6054.0 in Q2 2017.
  • Average Non-Current Deffered Revenue over 4 years is $18706.3, with a median of $19149.0 recorded in 2015.
  • Year-over-year, Non-Current Deffered Revenue rose 6.93% in 2016 and then crashed 75.44% in 2017.
  • Viking Therapeutics' Non-Current Deffered Revenue stood at $31239.0 in 2015, then crashed by 47.8% to $16307.0 in 2016, then plummeted by 62.87% to $6054.0 in 2017, then skyrocketed by 98.22% to $12000.0 in 2018.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $12000.0, $6054.0, and $10862.0 for Q4 2018, Q2 2017, and Q1 2017 respectively.